190 related articles for article (PubMed ID: 10202232)
21. Levofloxacin in the treatment of community-acquired pneumonia.
Noreddin AM; Elkhatib WF
Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.
Norrby SR; Petermann W; Willcox PA; Vetter N; Salewski E
Scand J Infect Dis; 1998; 30(4):397-404. PubMed ID: 9817522
[TBL] [Abstract][Full Text] [Related]
23. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
[TBL] [Abstract][Full Text] [Related]
24. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study.
Shah PM; Maesen FP; Dolmann A; Vetter N; Fiss E; Wesch R
J Antimicrob Chemother; 1999 Apr; 43(4):529-39. PubMed ID: 10350383
[TBL] [Abstract][Full Text] [Related]
25. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
26. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
27. [Clinical experience of levofloxacin in community acquired pneumonia].
Arancibia F; Maldonado A; Torres A
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():14-8. PubMed ID: 10563105
[No Abstract] [Full Text] [Related]
28. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
Zervos M; Mandell LA; Vrooman PS; Andrews CP; McIvor A; Abdulla RH; de Caprariis PJ; Knirsch CA; Amsden GW; Niederman MS; Lode H
Treat Respir Med; 2004; 3(5):329-36. PubMed ID: 15606222
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
31. Levofloxacin: an updated review of its use in the treatment of bacterial infections.
Hurst M; Lamb HM; Scott LJ; Figgitt DP
Drugs; 2002; 62(14):2127-67. PubMed ID: 12269858
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of community-acquired pneumonia with levofloxacin: 500 mg once a day or 500 mg twice a day?].
Zuck P; Bru JP
Presse Med; 2000 May 27-Jun 3; 29(19):1062-5. PubMed ID: 10874918
[TBL] [Abstract][Full Text] [Related]
33. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
Budanov SV; Vasil'ev AN; Smirnova LB
Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
[No Abstract] [Full Text] [Related]
34. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Yong DE; Cheong HJ; Kim YS; Park YJ; Kim WJ; Woo JH; Lee KW; Kang MW; Choo YS
J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
[TBL] [Abstract][Full Text] [Related]
36. [Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia].
Sánchez ME; Gómez J; Gómez Vargas J; Baños V; Ruiz Gómez J; Muñoz L; Simarro E; Soto MC; Canteras M; Valdés M
Rev Esp Quimioter; 1998 Jun; 11(2):132-8. PubMed ID: 9795298
[TBL] [Abstract][Full Text] [Related]
37. Levofloxacin for the treatment of community-acquired pneumonia.
Lynch JP; File TM; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):725-42. PubMed ID: 17140350
[TBL] [Abstract][Full Text] [Related]
38. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Marrie TJ
Chemotherapy; 2004; 50 Suppl 1():11-5. PubMed ID: 15319549
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.
Mendes C; Kiffer CR; Blosser-Middleton RS; Jones ME; Karlowsky JA; Barth A; Rossi F; Andrade S; Sader HS; Thornsberry C; Sahm DF;
Clin Microbiol Infect; 2004 Jun; 10(6):521-6. PubMed ID: 15191379
[TBL] [Abstract][Full Text] [Related]
40. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
